Research Article
Equipping the American Joint Committee on Cancer Staging for Resectable Pancreatic Ductal Adenocarcinoma with Tumor Grade: A Novel Staging System
Table 1
Baseline clinicopathologic characteristics.
| Characteristics | Training set (n = 4983) (%) | Internal validation set (n = 4983) (%) | External validation set (n = 324) (%) |
| Age, yrs | <65 | 2172 (43.6) | 2185 (43.8) | 212 (65.4) | ≥65 | 2811 (56.4) | 2798 (56.2) | 112 (34.6) |
| Sex | Male | 2461 (49.4) | 2478 (49.7) | 136 (42.0) | Female | 2522 (50.6) | 2505 (50.3) | 188 (58.0) |
| Location | Head | 3832 (76.8) | 3842 (77.1) | 161 (49.7) | Body and tail | 704 (14.2) | 717 (14.4) | 163 (50.3) | Other | 447 (9.0) | 424 (8.5) | 0 (0) |
| Year of diagnosis | 2004–2009 | 2049 (41.1) | 2010 (40.3) | — | 2010–2015 | 2934 (58.9) | 2973 (59.7) | — |
| Grade | Low grade | 3063 (61.5) | 3115 (62.5) | 165 (50.9) | High grade | 1920 (38.5) | 1868 (37.5) | 159 (49.1) |
| Examined lymph nodes | <15 | 2187 (46.1) | 2221 (46.6) | 183 (56.5) | ≥15 | 2558 (53.9) | 2547 (53.4) | 141 (43.5) |
| 7th AJCC stage | IA | 188 (3.8) | 192 (3.9) | 7 (2.2) | IB | 270 (5.4) | 292 (5.9) | 36 (11.1) | IIA | 1105 (22.2) | 1081 (21.7) | 130 (40.1) | IIB | 3418 (68.6) | 3417 (68.5) | 151 (46.6) |
| 8th T stage | T1 | 833 (16.7) | 801 (16.1) | 44 (13.5) | T2 | 2928 (58.8) | 3023 (60.7) | 179 (54.9) | T3 | 1222 (24.5) | 1159 (23.3) | 103 (31.6) |
| 8th N stage | N0 | 1610 (32.3) | 1591 (31.9) | 180 (55.2) | N1 | 2084 (41.8) | 2114 (42.4) | 112 (34.4) | N2 | 1289 (25.9) | 1278 (25.6) | 34 (10.4) |
| Extrapancreatic invasion 8th AJCC stage | 4106 (82.4) | 4100 (82.3) | 250 (76.7) | IA | 393 (7.9) | 379 (7.6) | 24 (7.4) | IB | 886 (17.8) | 885 (17.8) | 97 (29.9) | IIA | 331 (6.6) | 327 (6.6) | 58 (17.9) | IIB | 2084 (41.8) | 2114 (42.4) | 111 (34.3) | III | 1289 (25.9) | 1278 (25.6) | 34 (10.5) |
| Median OS (95% CI) | 19 (18.4–19.6) | 19.0 (18.4–19.6) | 23.6 (19.4–27.8) |
|
|
Values in parentheses are percentages.
|